To validate the predictive value of the three-gene (ADH1C, SLC26A2, and NANS) signature in patients with CRC who underwent fluoropyrimidine-based chemotherapy, two GEO datasets (GSE104645, n=193; GSE28702, n=83) were screened, which provided the response status data of CRC patients who underwent FOLFOX or FOLFOX-based regimens. Here, SLC26A2 is linked to colorectal carcinoma.